WO2003015605A3 - Use of s-nitrosothiol signaling to treat disordered control of breathing - Google Patents

Use of s-nitrosothiol signaling to treat disordered control of breathing Download PDF

Info

Publication number
WO2003015605A3
WO2003015605A3 PCT/US2002/025199 US0225199W WO03015605A3 WO 2003015605 A3 WO2003015605 A3 WO 2003015605A3 US 0225199 W US0225199 W US 0225199W WO 03015605 A3 WO03015605 A3 WO 03015605A3
Authority
WO
WIPO (PCT)
Prior art keywords
breathing
csno
control
directed
disordered control
Prior art date
Application number
PCT/US2002/025199
Other languages
French (fr)
Other versions
WO2003015605A2 (en
Inventor
Benjamin M Gaston
David Gozal
Original Assignee
Univ Virginia
Univ Louisville Res Found
Benjamin M Gaston
David Gozal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Virginia, Univ Louisville Res Found, Benjamin M Gaston, David Gozal filed Critical Univ Virginia
Priority to US10/487,060 priority Critical patent/US7432301B2/en
Priority to AU2002326573A priority patent/AU2002326573B2/en
Priority to CA002459647A priority patent/CA2459647A1/en
Priority to EP02761296A priority patent/EP1427323A4/en
Publication of WO2003015605A2 publication Critical patent/WO2003015605A2/en
Publication of WO2003015605A3 publication Critical patent/WO2003015605A3/en
Priority to US12/207,042 priority patent/US20090004298A1/en
Priority to AU2009200028A priority patent/AU2009200028A1/en
Priority to US13/072,979 priority patent/US20110177000A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Abstract

The present invention is directed to a method of treating disordered control of breathing including the treatment of apnea and hypoventilation associated with congenital or acquired brain stem abnormalities. Specifically the invention is directed to treating disordered control of breathing by administering an S-nitrosylating agent selected from the group consisting of ethyl nitrite, glutathione, nitric oxide, S-nitrosocysteine, S-nitrosoglutathione, S-nitro-N-acetyl cysteine. As shown in Fig. 1C the ability of endogenous SNOs to increase VE in freely behaving, conscious rates using whole-body plethysmography revealed that CSNO, GSNO and CGSNO (1nmol each) caused equivalent increases in VE, whereas D-CSNO had no effect (left bar graph is the equivalent increases in VE, whereas D-CSNO had no effect (left bar graph is the control whereas the right bar represents administration of the respective SNO).
PCT/US2002/025199 2001-08-20 2002-08-12 Use of s-nitrosothiol signaling to treat disordered control of breathing WO2003015605A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
US10/487,060 US7432301B2 (en) 2001-08-20 2002-08-12 Use of S-nitrosothiol signaling to treat disordered control of breathing
AU2002326573A AU2002326573B2 (en) 2001-08-20 2002-08-12 Use of S-nitrosothiol signaling to treat disordered control of breathing
CA002459647A CA2459647A1 (en) 2001-08-20 2002-08-12 Use of s-nitrosothiol signaling to treat disordered control of breathing
EP02761296A EP1427323A4 (en) 2001-08-20 2002-08-12 Use of s-nitrosothiol signaling to treat disordered control of breathing
US12/207,042 US20090004298A1 (en) 2001-08-20 2008-09-09 Use of S-Nitrosothiol Signaling to Treat Disordered Control of Breathing
AU2009200028A AU2009200028A1 (en) 2001-08-20 2009-01-02 Use of S-nitrosothiol signaling to treat disordered control of breathing
US13/072,979 US20110177000A1 (en) 2001-08-20 2011-03-28 Use of S-Nitrosothiol Signaling to Treat Disordered Control of Breathing

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31354801P 2001-08-20 2001-08-20
US60/313,548 2001-08-20

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/207,042 Continuation US20090004298A1 (en) 2001-08-20 2008-09-09 Use of S-Nitrosothiol Signaling to Treat Disordered Control of Breathing

Publications (2)

Publication Number Publication Date
WO2003015605A2 WO2003015605A2 (en) 2003-02-27
WO2003015605A3 true WO2003015605A3 (en) 2003-11-13

Family

ID=23216162

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/025199 WO2003015605A2 (en) 2001-08-20 2002-08-12 Use of s-nitrosothiol signaling to treat disordered control of breathing

Country Status (5)

Country Link
US (3) US7432301B2 (en)
EP (1) EP1427323A4 (en)
AU (2) AU2002326573B2 (en)
CA (1) CA2459647A1 (en)
WO (1) WO2003015605A2 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8282967B2 (en) 2005-05-27 2012-10-09 The University Of North Carolina At Chapel Hill Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
US8591876B2 (en) 2010-12-15 2013-11-26 Novan, Inc. Methods of decreasing sebum production in the skin
US8981139B2 (en) 2011-02-28 2015-03-17 The University Of North Carolina At Chapel Hill Tertiary S-nitrosothiol-modified nitric—oxide-releasing xerogels and methods of using the same
US9526738B2 (en) 2009-08-21 2016-12-27 Novan, Inc. Topical gels and methods of using the same

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7432301B2 (en) * 2001-08-20 2008-10-07 University Of Virginia Patent Foundation Use of S-nitrosothiol signaling to treat disordered control of breathing
WO2004100989A1 (en) * 2003-05-19 2004-11-25 Ajinomoto Co., Inc. Preventives/remedies for snore or respiratory disturbances during sleep
EP1940369A4 (en) * 2005-09-20 2011-01-26 Galleon Pharmaceuticals Inc Combination s-nitrosothiol-based pharmaceutical products for restoring normal breathing rhythm
AU2007325972A1 (en) * 2006-10-03 2008-06-05 Galleon Pharmaceuticals, Inc. S-nitrosothiol compounds and related derivatives
US7943667B2 (en) * 2007-10-11 2011-05-17 Duke University Potentiating the effect of compound comprising nitric oxide
US8741937B2 (en) 2008-02-04 2014-06-03 The Board Of Regents Of The University Of Oklahoma Gamma glutamyl transpeptidase inhibitors and methods of use
WO2009100121A1 (en) * 2008-02-04 2009-08-13 The Board Of Regents Of The University Of Oklahoma Gamma-glutamyl transpeptidase inhibitors and methods of use
WO2009151744A1 (en) * 2008-04-02 2009-12-17 Galleon Pharmaceuticals, Inc. S-nitrosomercapto compounds and related derivatives
WO2010044875A2 (en) * 2008-10-16 2010-04-22 Novan, Inc. Nitric oxide releasing particles for oral care applications
WO2010051532A1 (en) * 2008-10-31 2010-05-06 University Of Chicago Compositions and methods related to obstructive sleep apnea
BR112012003804B1 (en) 2009-08-21 2019-02-19 Novan, Inc. Wound Dressing, Method to Form an Injury Dressing, and Wound Dressing Kit
EP2488591A1 (en) * 2009-10-13 2012-08-22 Novan, Inc. Nitric oxide-releasing coatings
WO2012166991A1 (en) * 2011-05-31 2012-12-06 The Board Of Regents Of The University Of Texas Systeem S-nitrosylation of glucosylating toxins and uses therefor
US9540337B2 (en) 2012-03-23 2017-01-10 The Board Of Regents Of The University Of Oklahoma Gamma-glutamyl transpeptidase inhibitors and methods of use
WO2015017383A2 (en) 2013-07-31 2015-02-05 The Children's Hospital Of Philadelphia Compositions and methods of the treatment of fatty acid metabolism disorders
WO2015165947A1 (en) * 2014-04-29 2015-11-05 Tima Foundation Composition against sleep apnea
US11045441B2 (en) * 2015-10-13 2021-06-29 Wisconsin Alumni Research Foundation Use of retinoic acid and analogs thereof to treat central neural apneas
US10590063B2 (en) 2015-11-06 2020-03-17 The Children's Hospital Of Philadelphia Compositions and methods for the treatment of fatty acid metabolism disorders

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5570683A (en) * 1990-12-05 1996-11-05 The General Hospital Corporation Methods and devices for treating pulmonary vasoconstriction and asthma
US6314956B1 (en) * 1999-09-08 2001-11-13 Duke University Pulmonary delivery of NO group-containing compound in gas form to treat respiratory, cardiac and blood disorders

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4900719A (en) * 1988-08-05 1990-02-13 The Ohio State University Nitrosothiols as hypotensive agents
IL101406A (en) * 1991-03-29 1998-02-08 Brigham & Womens Hospital Pharmaceutical compositions containing s-nitrosothiol derivatives
US5380758A (en) * 1991-03-29 1995-01-10 Brigham And Women's Hospital S-nitrosothiols as smooth muscle relaxants and therapeutic uses thereof
EP0593456B1 (en) 1991-04-03 1997-01-22 Eastman Kodak Company Manufacture of aromatic amines
EP1025853A3 (en) * 1991-11-14 2000-11-08 Brigham And Women's Hospital Pharmaceutical composition containing S-nitroso-heme proteins and use thereof
US5508045A (en) * 1992-10-09 1996-04-16 The Regents Of The University Of California Method and agents for control and management of labor during pregnancy
US5427797A (en) * 1993-04-06 1995-06-27 Brigham And Women's Hospital Systemic effects of nitric oxide inhalation
GB9320978D0 (en) * 1993-10-12 1993-12-01 Higenbottam Timohy W Nitric oxide treatment
US5612314A (en) * 1995-04-21 1997-03-18 Brigham & Women's Hospital Nitrosylated neuropeptides
US6331543B1 (en) * 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
EP0979073A4 (en) * 1997-03-31 2004-04-07 Childrens Medical Center Nitrosylation to inactivate apoptotic enzymes
WO2000001351A1 (en) * 1998-07-07 2000-01-13 Transdermal Technologies, Inc. Compositions for rapid and non-irritating transdermal delivery of pharmaceutically active agents and methods for formulating such compositions and delivery thereof
AU6028599A (en) * 1998-09-09 2000-03-27 Scios Inc. Methods of treating hypertension and compositions for use therein
US6555564B1 (en) * 1999-03-04 2003-04-29 The Board Of Trustees Of The University Of Illinois Neuropharmacological treatments of sleep-related breathing disorders
WO2001062290A2 (en) * 2000-02-22 2001-08-30 Cellegy Canada Inc. Methods and compositions for improving sleep
US20020002136A1 (en) * 2000-06-28 2002-01-03 Hebert Rolland F. Salts of glutathione
CA2425489C (en) * 2000-10-16 2011-05-17 Duke University Therapeutic use of aerosolized s-nitrosoglutathione in cystic fibrosis
US20020069877A1 (en) * 2000-12-13 2002-06-13 Villareal Daniel C. Ventilation transport device
US7432301B2 (en) * 2001-08-20 2008-10-07 University Of Virginia Patent Foundation Use of S-nitrosothiol signaling to treat disordered control of breathing

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5570683A (en) * 1990-12-05 1996-11-05 The General Hospital Corporation Methods and devices for treating pulmonary vasoconstriction and asthma
US6314956B1 (en) * 1999-09-08 2001-11-13 Duke University Pulmonary delivery of NO group-containing compound in gas form to treat respiratory, cardiac and blood disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1427323A4 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8282967B2 (en) 2005-05-27 2012-10-09 The University Of North Carolina At Chapel Hill Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
US8956658B2 (en) 2005-05-27 2015-02-17 The University Of North Carolina At Chapel Hill Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
US8962029B2 (en) 2005-05-27 2015-02-24 The University Of North Carolina At Chapel Hill Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
US9403851B2 (en) 2005-05-27 2016-08-02 The University Of North Carolina At Chapel Hill Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
US9403852B2 (en) 2005-05-27 2016-08-02 The University Of North Carolina At Chapel Hill Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
US9526738B2 (en) 2009-08-21 2016-12-27 Novan, Inc. Topical gels and methods of using the same
US8591876B2 (en) 2010-12-15 2013-11-26 Novan, Inc. Methods of decreasing sebum production in the skin
US8981139B2 (en) 2011-02-28 2015-03-17 The University Of North Carolina At Chapel Hill Tertiary S-nitrosothiol-modified nitric—oxide-releasing xerogels and methods of using the same

Also Published As

Publication number Publication date
WO2003015605A2 (en) 2003-02-27
US20090004298A1 (en) 2009-01-01
US7432301B2 (en) 2008-10-07
AU2009200028A1 (en) 2009-02-05
CA2459647A1 (en) 2003-02-27
US20040224899A1 (en) 2004-11-11
AU2002326573B2 (en) 2008-10-02
EP1427323A4 (en) 2004-09-15
EP1427323A2 (en) 2004-06-16
US20110177000A1 (en) 2011-07-21

Similar Documents

Publication Publication Date Title
WO2003015605A3 (en) Use of s-nitrosothiol signaling to treat disordered control of breathing
BR0313282A (en) Selective cyclooxygenase-2 inhibitor compositions and a carbonic anhydrase inhibitor for the treatment of neoplasia
DK1411932T3 (en) Combination therapy with substituted oxazolidinones
MX2010002498A (en) Methods of treating or preventing respiratory tract infection comprising administering cholecalciferol.
WO2002078627A3 (en) N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity
WO2010030180A3 (en) Peptide formulations and uses thereof
EP2583680A3 (en) Mono (PSI-7977) or combination treatment of DAAs for use in treating HCV
WO2006023702A3 (en) Method for treating sleep related breathing disorders with setiptiline
WO2006029036A3 (en) Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis
WO2005116233A3 (en) Composition and method of cancer treatment
TW200724146A (en) Use of LGG in the manufacture of a medicament for the treatment, prevention or reduction of systemic inflammation in a formula-fed infant
WO2004110420A8 (en) Treatment and prevention of excessive scarring with 4-hydroxy tamoxifen
BR0310061A (en) Methods for treating respiratory diseases and conditions with a selective inhibitor of inos and a inhibitor of pde and their compositions
UA72927C2 (en) Docetaxel-containing composition for treating hepatocellular carcinoma
EA200700979A1 (en) ORAL SOLID MEDICINE FORMS CONTAINING LOW DOSE OF ESTRADIOL
TW200511999A (en) Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and parathyroid hormone
WO2005032453A3 (en) Antiviral agents for the treatment, control and prevention of infections by coronaviruses
WO2004026118A3 (en) Administration of free radical scavengers to prevent or treat ischemia-reperfusion injuries
BR0311180A (en) Methods for treating respiratory diseases and conditions using a selective inhibitor of inos
WO2008080682A3 (en) Synergistic combination of silk proteins and select metals
EA200601853A1 (en) TREATMENT OF DISTURBED RESPIRATORY FUNCTION
EA200501625A1 (en) INTERFERON-BETA WITH A HEAVY ACUTE RESPIRATOR SYNDROME (SARS)
AU2003230830A8 (en) Treatment of type 1 diabetes before and after expression of predisposition markers
TW200608965A (en) Medicine for prevention or treatment of diabetes
MX2022006884A (en) Chronic wound healing composition and application thereof.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 10487060

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2002326573

Country of ref document: AU

Ref document number: 2459647

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002761296

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002761296

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP